Inhibiting or harnessing fratricide in CAR-engineered cell therapy: challenges and opportunities

Authors: Gorobchenko, Andrew N; Umbetova, Karina T; Gadaev, Abdigaffor; Mahkamova, Nargiza; Sabirova, Nasiba; Kubaev, Aziz

Source journal: Cancer chemotherapy and pharmacology (2026-11-18)

DOI: 10.1007/s00280-026-04979-6

Abstract

Chimeric antigen receptor (CAR)-engineered cell therapy has transformed the therapeutic landscape of certain blood cancers; however, extending it to new disease settings has not yet succeeded. Among several well-recognized barriers to broader success, including antigen heterogeneity and escape, limited trafficking to tumor sites, poor in vivo persistence, and the immunosuppressive tumor microenvironment, fratricide represents an additional important challenge. This phenomenon arises when the CAR target antigen is also naturally expressed on CAR-engineered cells or induced during cell activation, leading to unintended recognition and destruction of the therapeutic cells by their counterparts. It can also arise through less direct pathways, such as trogocytosis- or extracellular vesicle (EV)-mediated antigen transfer, which can make CAR-engineered cells vulnerable to fratricide because they do not naturally express the target antigen. Biologically, fratricide is a very significant mechanism that can impair cell expansion during manufacturing, reduce product yield and fitness, promote exhaustion, and compromise persistence after infusion. This review examines the biological basis of both target-intrinsic and acquired-antigen fratricide across CAR-engineered cell therapies. We comprehensively discuss current strategies to prevent fratricide, including antigen knockout or knockdown, intracellular protein retention, transient pharmacologic suppression of CAR signaling, selective enrichment of antigen-negative cells, inhibition of trogocytosis or EV pathways, and alternative receptor designs such as inhibitory, bispecific, and tandem CARs. We also review clinical advances in fratricide-resistant CAR-T cells and summarize related clinical trials. Finally, we consider an emerging counterpoint: under controlled conditions, fratricide may be deliberately exploited to enrich desirable cell populations. Mechanistic understanding of fratricide and its preventive strategies can help to develop safer and more efficacious CAR-engineered cellular therapies.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.